MCK Stock Recent News

Both McKesson and Cardinal Health dominate drug distribution, but which stock offers better growth and stability in 2025? Here we discuss which company has better long-term potential.

Investors often turn to recommendations made by Wall Street analysts before making a Buy, Sell, or Hold decision about a stock. While media reports about rating changes by these brokerage-firm employed (or sell-side) analysts often affect a stock's price, do they really matter?

McKesson's MCK shares have gained 4.4% following its fourth-quarter fiscal 2025 earnings release on May 9. The post-earnings upside reflects growing investor confidence in McKesson's strategic execution and long-term positioning, underpinned by record full-year revenues of $359 billion and a 20% year-over-year increase in adjusted earnings per share (to $33.05).

The stock price of McKesson has maintained a strong upward trend throughout multiple years because of its solid financial performance and dedicated investor support which creates a defensive investment opportunity. The company achieves strong revenue and EPS growth through its expanding oncology, biopharmaceutical and GLP-1 therapy sales, which counterbalance the typical thin margins of the sector. The company's strategic focus on high-growth segments together with its divestment of slow-growth units makes McKesson an attractive long-term investment despite its high valuation and low yield.

The article provides a methodology for selecting high-growth dividend-paying stocks, focusing on dividend growth and sustainability rather than high current yield. We use our proprietary models to rate quantitatively and qualitatively, and select the top ten names from an initial list of nearly 400 dividend stocks. The final list of ten stocks is chosen based on sector diversity, high-growth quality scores, and positive momentum, suitable for investors in the accumulation phase.

Deal OverviewOn May 8, 2025, McKesson Corporation (NYSE: MCK, $682.28, Market Capitalization: $85.4 billion), a diversified healthcare services company, announced its intention to separate its Medical-Surgical Solutions segment into an independent company (NewCo) (for more information, visit spinoffresearch.com). McKesson is committed to exploring all opportunities to execute a separation in a manner that maximizes shareholder value and anticipates providing more information as appropriate on the form and timing as the process progresses.

McKesson (MCK) possesses solid growth attributes, which could help it handily outperform the market.

Zacks.com users have recently been watching McKesson (MCK) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.

McKesson Corporation (NYSE:MCK ) BofA Securities 2025 Healthcare Conference May 13, 2025 11:00 AM ET Company Participants Britt Vitalone - Chief Financial Officer Conference Call Participants Allen Lutz - Bank of America Allen Lutz Welcome to day one of the BofA Healthcare Conference here in Las Vegas. We are very excited to welcome McKesson here.

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.